JAK2 mutations in Asian patients with essential thrombocythaemia
Background/Aim: JAK2V617F is an acquired mutation present in a considerable proportion of patients with chronic myeloproliferative disorders. Its reported prevalence in European and US studies of patients with essential thrombocythaemia (ET) is 23–57%. This study was conducted to determine the prevalence of the JAK2 mutation in Asian ET patients, and to examine their disease profile.
No Supplementary Data
Document Type: Research Article
Publication date: 2011-02-01